,

Rev Esp Quimioter 2019; 32(Suppl. 2):55-58

Update on the management of febrile neutropenia in hematologic patients  

FRANCESC ESCRIHUELA-VIDAL. JÚLIA LAPORTE, ADAIA ALBASANZ-PUIG, CARLOTA GUDIOL

Febrile neutropenia is a common complication in patients with hematologic malignancies receiving chemotherapy, and is associated with high morbidity and mortality. Infections caused by multidrug-resistant bacteria represent a therapeutic challenge in this high-risk patient population, since inadequate initial empirical antibiotic treatment can seriously compromise prognosis. Besides, reducing antimicrobial exposure is a cornerstone in the fight against resistance.

Rev Esp Quimioter 2019; 32(Suppl. 2):55-58 [Full-text PDF]

 

 

/por
Rev Esp Quimioter 2019; 32(Suppl. 2):47-54Rev Esp Quimioter 2019; 32(Suppl. 2):59-62